Chronic Leukemias is a new study from Decision Resources, Inc., that evaluates the market prospects for emerging therapies to treat two of the most prevalent leukemias: chronic lymphocytic leukemia (CLL) and chronic myelogenous leukemia (CML). The findings of this study indicate that the chronic leukemias are a fertile ground for drug development. The introduction of premium-priced compounds to treat CML and CLL and their rapid, widespread uptake is set to revolutionize medical practice and fuel huge market growth in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) through 2010.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

We anticipate dramatic growth in the CLL market over the 2000-2010 forecast period of this study. By 2005, market newcomers alemtuzumab (Schering's Campath) and rituximab (Idec/Genentech's Rituxan/MabThera) will garner significant sales because of their high prices and anticipated widespread use.

CML is a market in which we anticipate enormous change over the course of our study period. Market growth will be most rapid between 2000 and 2005. The following factors will trigger this period's nearly 50% annual growth rate:

  -- Licensing and rapid uptake of Novartis's signal transduction inhibitor      imatinib (Gleevec) and pegylated IFN-alpha.   -- An increase in the number of patients receiving long-term      pharmaceutical therapy because of a reduction in the use of allogeneic      progenitor stem-cell transplant (AlPSCT).  

During the second half of the forecast period, the rate of growth will slow but remain robust. Over this period, the following factors will drive growth:

  -- An increase in the number of patients receiving imatinib and pegylated      IFN-alpha as first-line therapy.   -- An increase in the duration of drug treatment given that both imatinib      and pegylated IFN-alpha increase survival times.  

Chronic Leukemias offers invaluable market intelligence for pharmaceutical companies developing drugs to treat these diseases. This study is part of Onkos, one of six Pharmacor services available from Decision Resources that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at http://www.dresources.com/.

Contact Frank Sama, 781.296.2553 (tel), 781.296.2550 (fax), or sama@dresources.com. In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or fbidart@decisionresources.be. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X48279722

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,
sama@dresources.com

Decision Resources Elects Mary Carrigan Vice President of Human Resources

View Now